Opinion|Videos|April 24, 2024

EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer

Dr O’Dea provides an overview of the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer and discusses subgroup analysis data and their clinical implications.


Latest CME